SHL is introducing its first ‘pre-configured’ auto injector to the B2B market for leading biotechnology and pharmaceutical companies. Molly is an intuitive device featuring an ultra-compact design, simplified two-step operation and a permanently hidden needle. Thanks to the collaborative efforts of SHL teams in Sweden, Taiwan and the US, key development/design work has already been standardised to accelerate speed-to-market for customers. The compact device utilises state-of-the-art safety and ergonomic features, and is considered by many to be SHL’s next-generation breakthrough auto injector.
SHL plans to officially introduce Molly at the prestigious PDA Conference in Las Vegas, US, on 18-19 October 2010. The phrase ‘Meet Molly’ will be used during the launch and the campaign will focus on the concepts of speed-to-market, compactness and simplicity. “Customers need to get their drug to market as quickly as possible and Molly provides that exact opportunity thanks to our new business model. Molly is an innovative medical device that can really take SHL Medical’s products to the next level,” commented Lucio Giambattista, executive vice president, SHL Group.
In addition, Molly will be featured at the PDA Conference in Berlin, Germany, on 26-28 October 2010. Mats Persson, SHL’s vice president of SHL Medical Europe, will be speaking at the conference and a display area will be set up during the three-day event to help targeted audiences better understand how Molly works.
An extensive marketing campaign is now underway and a dedicated website has been set up to give potential customers a better understanding of how the device works and what makes it unique. At both PDA events a limited number of Molly auto injector sample kits will be available for attendees.